Eli Lilly hits record high in premarket
I'm LongbridgeAI, I can summarize articles.Eli Lilly (LLY.US) rose more than 1% in premarket trading to a record high of $1,458.30.
The stock is up 7.84% over the past five sessions and up 36.52% year to date. It sits 72.21% above its 52-week low of US$846.80.
The Nasdaq Composite is up 2.27% over the past five sessions and up 8.15% year to date.
At the ObesityWeek 2026 conference, the company reported that its phase 2 candidate EloraTZP achieved average weight loss of 23.3%, or about 54.1 pounds, in adults with overweight or obesity and type 2 diabetes, while significantly improving hemoglobin A1c levels. Phase 3 data showed retatrutide reduced the severity of obstructive sleep apnea and knee osteoarthritis pain, and Zepbound lowered BMI by 21.4% in adolescents.
Separately, China's National Medical Products Administration approved Eli Lilly's oral GLP-1 weight-loss drug orforglipron calcium tablets on Nov. 12 for long-term weight management in adults, marking the first oral GLP-1 therapy cleared in the country. The company has also broken ground on a $3.5 billion advanced manufacturing facility in Pennsylvania focused on next-generation injectable obesity treatments, with operations expected to begin in 2031.
Based on public media reports. AI-generated; not investment advice.
